Company Monitoring Page for Biomarin

latest headlines for company on cafepharma

Update: BioMarin To Acquire Prosensa Holding N.V.
Seeking Alpha
Thu, 01/15/15 - 12:03 pm
Tags:
Biomarin, Prosensa, M&A
Shire’s Next Targets Could Be on This List: Real M&A
Bloomberg
Wed, 01/14/15 - 10:00 am
Tags:
Shire, M&A, PTC Therapeutics, SynaGeva BioPharma, Retrophin, Ultragenyx, Vertex Pharmaceuticals, Biomarin
BioMarin CEO Sees Big Future For Prosensa Drug
Investors.com
Wed, 12/24/14 - 08:58 am
Tags:
Biomarin, Prosensa, drisapersen, Duchenne Muscular Dystrophy
J.P. Morgan's 6 Top Biotech and Pharmaceuticals Stocks to Buy in 2015
TheStreet.com
Mon, 12/22/14 - 09:47 am
Tags:
Alexion, Biomarin, Bristol-Myers Squibb, Jazz Pharmaceuticals, Valeant Pharmaceuticals, Illumina
BioMarin Expands Reach By Buying Prosensa for Up to $840 Million
TheStreet.com
Mon, 11/24/14 - 09:42 am
Tags:
Biomarin, Prosensa, M&A
The top 10 most expensive drugs of 2013
Fierce Pharma
Tue, 10/14/14 - 10:05 am
Tags:
drug pricing, Soliris, Alexion, Naglazyme, Biomarin, Kalydeco, Vertex, Cinryze, Shire, Sprycel, Bristol-Myers Squibb, Pomalyst, Celgene, Xyrem, Jazz Pharmaceuticals, Erbitux, Merck KGaA, Revlimid, Questcor, Mallinckrodt, H.P. Acthar Gel
5 Orphan Drug Biotech Stocks to Buy With Big Upside Potential
24/7 Wall St
Thu, 09/25/14 - 09:20 am
Tags:
orphan drugs, Alnylam, Biomarin, Alexion, Isis Pharmaceuticals, Vertex Pharmaceuticals
BioMarin's Q1 Loss Shrinks 79% Due to Higher Rare Disease Drug Sales
Motley Fool
Fri, 05/2/14 - 08:38 am
Tags:
Biomarin, earnings
Loss at BioMarin Narrower Than Expected
Yahoo/Zacks.com
Thu, 02/27/14 - 11:26 am
Tags:
earnings, Biomarin
BioMarin and its patient coaches are ready to roll on Vimizim launch
Fierce Pharma
Mon, 02/17/14 - 07:48 pm
Tags:
Biomarin, Vimizim, drug launches
FDA approves BioMarin's genetic disorder drug Vimizim
Yahoo/Reuters
Fri, 02/14/14 - 06:29 pm
Tags:
Biomarin, FDA, Vimizim, Morquio A Syndrome
This Week in Biotech: Clinical Success, Plus Wheeling and Dealing
Motley Fool
Sun, 01/26/14 - 10:46 am
Tags:
BioDelivery Sciences, Endo Health Solutions, Karyopharm Therapeutics, Repligen, Biomarin, Ariad Pharmaceuticals, Eli Lilly, GSK, Shire
Drugmakers see innovation justifying further price rises
Reuters
Fri, 01/17/14 - 05:44 pm
Tags:
innovation, Biomarin, Roche, Herceptin, Biogen Idec
UBS Has Nine Biotech Buyout and Merger Candidates
24/7 Wall St
Tue, 01/14/14 - 09:07 am
Tags:
biotech, M&A, Alexion, Biomarin, Incyte, Medivation, Idenix, Insmed, InterMune, Puma Biotechnology, Vertex Pharmaceuticals
What’s Next for Biotech?
Barron's
Fri, 01/10/14 - 06:47 pm
Tags:
Celgene, Alexion, Incyte, Biomarin
22 Biotech Stock Predictions for 2014
TheStreet.com
Mon, 01/6/14 - 09:47 am
Tags:
biotech, Vertex Pharmaceuticals, Orexigen, Retrophin, Valeant Pharmaceuticals, Questcor, Biomarin, Merck, NeoStem, Amgen, Gilead Sciences, Vanda, Keryx, Peregrine Pharmaceuticals, CelSci, Regeneron, Cempra, Dendreon, Clovis Oncology, Halozyme, NPS Pharmaceuticals
What Does the ViroPharma Buyout Mean for BioMarin?
Motley Fool
Mon, 12/30/13 - 12:06 pm
Tags:
ViroPharma, M&A, Biomarin, Shire
3 Lessons Big Pharma Learned From BioMarin in 2013
Motley Fool
Sun, 12/8/13 - 12:08 pm
Tags:
Biomarin
Galena: A Pipeline Rich For Investors
Seeking Alpha
Mon, 12/2/13 - 08:29 am
Tags:
Galena Biopharma, INSYS Therapeutics, Biomarin, NeuVax
2014 FDA Drug Approval Decision Calendar
TheStreet.com
Wed, 11/27/13 - 08:39 am
Tags:
FDA, drug approvals, GSK, Gilead, Theravance, Auxilium, Amarin, Bristol-Myers Squibb, Biogen Idec, Pozen, Vanda, Chelsea Therapeutics, pSivida, Alimera, United Therapeutics, Biomarin, JNJ, Pharmacyclics, Celgene, MannKind, Santarus, AstraZeneca, Durata Therapeutics, Eli Lilly, Omeros, BioDelivery Sciences, Anacor, Keryx, Cubist Pharmaceuticals, Nektar

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.